Pharmacies

This bill changes the date when TennCare must report to the legislature about the costs and outcomes of a pilot program that allows pharmacists to manage medication therapy. Instead of reporting by April 15, the report will now be due by October 15 each year while the pilot program is ongoing. The bill amends several sections of Tennessee law related to healthcare and pharmacy practices.

TN SB2242 is a senate bill in the Tennessee 114th General Assembly, sponsored by Jack Johnson (R), currently “Introduced” since February 2, 2026.

We track 9,160 Tennessee bills this session, 353 of them sponsored by Jack Johnson.

Supporters of the bill argue that moving the reporting date provides more time for analysis and can lead to better insights into the effectiveness of the pharmacist-provided medication therapy management program. They believe this change will enhance patient care and ensure that the program is evaluated thoroughly before legislative review.

Critics may argue that delaying the report could hinder timely oversight of the pilot program and its impact on healthcare costs and patient outcomes. They might express concerns that this could lead to a lack of accountability and transparency in how the program is being implemented and evaluated.

Senator Jack Johnson, the sponsor of SB2242, has a significant personal financial interest in the healthcare sector through his role as Vice President of Client Relations at CIGNA Healthcare, a major health services and HMO provider. This position directly aligns with the bill's focus on pharmacies and the management of medication therapy, which could potentially enhance the services provided by CIGNA and similar entities. The bill seeks to amend reporting requirements related to the TennCare program, which may influence how healthcare services are delivered and reimbursed, thereby impacting the financial performance of companies like CIGNA.

Additionally, Johnson's ownership of a small business consulting firm may also intersect with the healthcare industry, although the specifics of this business are not detailed. The potential for personal financial gain through enhanced healthcare program management and pharmacy services raises concerns about conflicts of interest. While the bill does not directly benefit him in a clear-cut manner, the alignment of his employment with CIGNA and the bill's implications for healthcare services suggest a high risk of conflict.

Unlike federal analysis based on campaign donations, state analysis examines legislators' personal financial interests — their jobs, businesses, and investments.

Items marked "AI-researched" are generated from public sources but have not been independently verified. Verified data is sourced from official legislature websites and disclosure filings.